search
Back to results

Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters

Primary Purpose

Urinary Tract Infection, Bacteriuria

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Nitric Oxide impregnated catheter
Sponsored by
Enox Israel Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Urinary Tract Infection

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients before radical prostatectomy at the Department of Urology in Beilinson Medical Center, which will be catheterized for 7-14 days.
  2. Age: ≥ 18 years.
  3. Patients with a life expectancy of more than 12 months.
  4. The investigator has completed a medical history and a physical examination to assure that the patients meets all study enrollment criteria.
  5. The patient is willing and able to read, understand and sign the study specific informed consent form.

Exclusion Criteria:

  1. A urinary culture demonstrating UTI before surgery.
  2. A patient with an indwelling urinary catheter prior to surgery.
  3. Expected life expectancy of less than 12 months.
  4. Concurrent illness, disability or geographical residence that would hamper study participation.
  5. Patients with underlying diseases such as heart disease, lung disease, skin disease or infection involving the penis, scrotum and groin, immunocompromised patients (transplant recipients, HIV carriers) or any other disease or condition that according to the physician opinion will influence the study results.
  6. Patients with known urethral stricture.
  7. Patients with recurrent UTIs.
  8. Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Nitric oxide impregnated catheter

    Arm Description

    Outcomes

    Primary Outcome Measures

    Number of participants with adverse events associated with Nitric Oxide impregnated catheters
    Proportion of patients (%) who prematurely discontinued the study due to adverse events or severe adverse events associated with Nitric oxide impregnated catheters

    Secondary Outcome Measures

    Measuring biofilm forming bacteria on the surface of Nitric Oxide impregnated and non impregnated Foley catheters after indwelling for 7 to 14 days
    Measuring bacteriuria (by urine culture) for Nitric Oxide impregnated and non impregnated Foley catheters prior to insertion, 1 day after insertion, every day during hospitalization, on catheter removal day, and 30 days after catheterization
    Measuring number of urinary tract infection (UTI) events following catheterization with Nitric Oxide impregnated and non impregnated Foley catheters
    Proportion of patients (%) who prematurely discontinued the study for any reason

    Full Information

    First Posted
    October 19, 2014
    Last Updated
    December 23, 2015
    Sponsor
    Enox Israel Ltd
    Collaborators
    Rabin Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02277171
    Brief Title
    Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters
    Official Title
    Prospective, Phase I, Single-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters in Patients Undergoing Radical Prostatectomy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2014 (undefined)
    Primary Completion Date
    June 2015 (Actual)
    Study Completion Date
    September 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Enox Israel Ltd
    Collaborators
    Rabin Medical Center

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    According to the World Health Organization, hundreds of millions of patients are affected by health-care associated infections worldwide each year, resulting in prolonged hospital stays, long-term disabilities, deaths, and financial losses for health systems. The most common hospital-acquired infection is Urinary Tract Infection (UTI), accounting for almost 40% of all nosocomial infections. Most hospital-acquired UTIs are associated with catheterization. In fact, urinary catheter-related bacteriuria is the most common health care associated infection worldwide. Catheter-associated UTI (CAUTI) develops following adhesion of planktonic bacteria to the surface of the catheter and colonization, creating a persistent environment called a biofilm. The nature of biofilm structure together with the physiological attributes of biofilm organisms confers an inherent resistance to various antimicrobial agents such as antibiotics, disinfectants or germicides, augmenting the potential of these pathogens to cause infections in catheterized patients. Nitric oxide (NO) is a naturally-produced gas molecule with broad-spectrum antimicrobial activity. NO is used in the clinics to treat pulmonary hypertension in neonates and adults. Studies have shown that low-dose NO is associated with prevention of biofilm formation, biofilm dispersal and elimination of bacteria. It is suggested that NO prevents bacteria attachment to catheter surfaces and inhibits biofilm formation in a mechanism involving reduction and modification of proteins that mediate cell-substrate and cell-cell interactions. The investigators team, using a proprietary technology impregnate urinary catheters with NO (i.e. NO-impregnated catheters). These catheters release low concentration of NO following exposure to urine over a 14-day period. In vitro studies showed that NO-impregnated catheters prevent bacterial colonization and biofilm formation of Escherichia coli on exterior and luminal surfaces of the catheters. In addition, NO released from these catheters is able to eradicate up to 4log colony forming unit/ml of bacteria within the surrounding media. Moreover, NO-impregnated catheters exhibit superior performance compared to silver-coated catheters, and similar anti-infective properties compared to antibiotic-coated catheters. Primary objectives: To assess the safety and tolerability of NO-impregnated catheters in patients older than 18 years old undergoing radical prostatectomy and catheterized for 7-14 days.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urinary Tract Infection, Bacteriuria

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    15 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Nitric oxide impregnated catheter
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    Nitric Oxide impregnated catheter
    Intervention Description
    Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
    Primary Outcome Measure Information:
    Title
    Number of participants with adverse events associated with Nitric Oxide impregnated catheters
    Time Frame
    30-45 days
    Title
    Proportion of patients (%) who prematurely discontinued the study due to adverse events or severe adverse events associated with Nitric oxide impregnated catheters
    Time Frame
    30-45 days
    Secondary Outcome Measure Information:
    Title
    Measuring biofilm forming bacteria on the surface of Nitric Oxide impregnated and non impregnated Foley catheters after indwelling for 7 to 14 days
    Time Frame
    7-14 days
    Title
    Measuring bacteriuria (by urine culture) for Nitric Oxide impregnated and non impregnated Foley catheters prior to insertion, 1 day after insertion, every day during hospitalization, on catheter removal day, and 30 days after catheterization
    Time Frame
    30-45 days
    Title
    Measuring number of urinary tract infection (UTI) events following catheterization with Nitric Oxide impregnated and non impregnated Foley catheters
    Time Frame
    30-45 days
    Title
    Proportion of patients (%) who prematurely discontinued the study for any reason
    Time Frame
    30-45 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients before radical prostatectomy at the Department of Urology in Beilinson Medical Center, which will be catheterized for 7-14 days. Age: ≥ 18 years. Patients with a life expectancy of more than 12 months. The investigator has completed a medical history and a physical examination to assure that the patients meets all study enrollment criteria. The patient is willing and able to read, understand and sign the study specific informed consent form. Exclusion Criteria: A urinary culture demonstrating UTI before surgery. A patient with an indwelling urinary catheter prior to surgery. Expected life expectancy of less than 12 months. Concurrent illness, disability or geographical residence that would hamper study participation. Patients with underlying diseases such as heart disease, lung disease, skin disease or infection involving the penis, scrotum and groin, immunocompromised patients (transplant recipients, HIV carriers) or any other disease or condition that according to the physician opinion will influence the study results. Patients with known urethral stricture. Patients with recurrent UTIs. Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David Greenberg, prof.
    Organizational Affiliation
    ENOX
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    19884372
    Citation
    Regev-Shoshani G, Ko M, Miller C, Av-Gay Y. Slow release of nitric oxide from charged catheters and its effect on biofilm formation by Escherichia coli. Antimicrob Agents Chemother. 2010 Jan;54(1):273-9. doi: 10.1128/AAC.00511-09. Epub 2009 Nov 2.
    Results Reference
    background
    PubMed Identifier
    21820571
    Citation
    Regev-Shoshani G, Ko M, Crowe A, Av-Gay Y. Comparative efficacy of commercially available and emerging antimicrobial urinary catheters against bacteriuria caused by E. coli in vitro. Urology. 2011 Aug;78(2):334-9. doi: 10.1016/j.urology.2011.02.063.
    Results Reference
    background
    PubMed Identifier
    21261931
    Citation
    Barraud N, Storey MV, Moore ZP, Webb JS, Rice SA, Kjelleberg S. Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. Microb Biotechnol. 2009 May;2(3):370-8. doi: 10.1111/j.1751-7915.2009.00098.x. Epub 2009 Mar 13.
    Results Reference
    background
    PubMed Identifier
    18657857
    Citation
    Charville GW, Hetrick EM, Geer CB, Schoenfisch MH. Reduced bacterial adhesion to fibrinogen-coated substrates via nitric oxide release. Biomaterials. 2008 Oct;29(30):4039-44. doi: 10.1016/j.biomaterials.2008.07.005. Epub 2008 Jul 26.
    Results Reference
    background
    PubMed Identifier
    18313512
    Citation
    Ramritu P, Halton K, Collignon P, Cook D, Fraenkel D, Battistutta D, Whitby M, Graves N. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. Am J Infect Control. 2008 Mar;36(2):104-17. doi: 10.1016/j.ajic.2007.02.012.
    Results Reference
    background
    PubMed Identifier
    22508462
    Citation
    Siddiq DM, Darouiche RO. New strategies to prevent catheter-associated urinary tract infections. Nat Rev Urol. 2012 Apr 17;9(6):305-14. doi: 10.1038/nrurol.2012.68.
    Results Reference
    background
    PubMed Identifier
    24501490
    Citation
    Parida S, Mishra SK. Urinary tract infections in the critical care unit: A brief review. Indian J Crit Care Med. 2013 Nov;17(6):370-4. doi: 10.4103/0972-5229.123451.
    Results Reference
    background

    Learn more about this trial

    Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters

    We'll reach out to this number within 24 hrs